2024-07-17 13:00:00 ET
Summary
- ORIC Pharmaceuticals, Inc. expects updated results from the phase 1b study, using ORIC-114 for the treatment of patients with mutated NSCLC, in the 1st half of 2025.
- The global non-small cell lung cancer market size is projected to reach $36.9 billion by 2031; Still a good market opportunity to go after, even if only targeting mutant NSCLC patients.
- Collaboration supply agreements made with J&J and Bayer to advance ORIC-944 in combination with ERLEADA and NUBEQA for treatment of patients with mCRPC respectively.
- The company had cash of $331.5 million as of March 31st of 2024; Enough cash to fund its operations into late 2026.
The last time I spoke about ORIC Pharmaceuticals, Inc. ( ORIC ) it was in a Seeking Alpha article entitled “ ORIC Pharmaceuticals: Mid-2024 Prostate Cancer Program Update Could Lead To Gains. ” In that article, I mentioned the progress ORIC had made regarding the development of ORIC-944 for the treatment of patients with metastatic castration-resistant prostate cancer [mCRPC]. In a phase 1b study being used to treat patients with advanced prostate cancer, it demonstrated single-agent best-in-class PRC2 inhibition....
Read the full article on Seeking Alpha
For further details see:
ORIC Pharma: ORIC-114 Advancement To Phase 1b Expansion Study Could Yield Value